Poxel Acquires DeuteRx Drug Portfolio
PARIS – Dechert LLP advised Poxel, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, on its acquisition of DRX-065, a novel clinical stage drug candidate for the treatment of Nonalcoholic steatohepatitis (NASH), from privately-held clinical-stage biopharmaceutical company DeuteRx LLC. Poxel has also acquired a portfolio of additional deuterated drug candidates from DeuteRx for metabolic, specialty and rare diseases as part of this transaction.
DeuteRx received a cash amount supplemented by new ordinary shares representing 4.99% of Poxel’s current share capital. DeuteRx will also be able to receive milestone payments based on the development and future sales of these drug candidates. This strategic acquisition allows Poxel to expand its metabolic pipeline and to gain exclusive and worldwide ownership to DRX-065 which is currently in Phase 1 development.
The Paris-based Dechert team advising Poxel is led by corporate partner Francois Hellot, assisted by associates Quentin Durand and Aude Steinberg.
Read the French press release »
About Dechert
Dechert is a leading global law firm with 27 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
